Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Stockholders Equity of $7.91 billion for fiscal year 2025.
TEVA PHARMACEUTICAL INDUSTRIES LTD Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $7.91B | +47.2% |
| 2024 | $5.37B | -28.4% |
| 2023 | $7.51B | +1.6% |
| 2023 | $7.39B | -2.7% |
| 2023 | $7.59B | -10.7% |
| 2023 | $8.50B | +9.0% |
| 2022 | $7.80B | -17.9% |
| 2022 | $9.51B | -3.1% |
| 2022 | $9.81B | -4.6% |
| 2021 | $10.28B | +2.5% |
| 2020 | $10.03B | -28.2% |
| 2019 | $13.97B | -5.0% |
| 2018 | $14.71B | -15.3% |
| 2017 | $17.36B | -47.9% |
| 2016 | $33.34B | +12.0% |
| 2015 | $29.77B | +27.7% |
| 2014 | $23.31B | +3.3% |
| 2013 | $22.57B | -0.9% |
| 2012 | $22.77B | +2.6% |
| 2011 | $22.20B | +1.1% |
| 2010 | $21.95B | +14.2% |
| 2009 | $19.22B | +17.4% |
| 2008 | $16.38B | +18.1% |
| 2007 | $13.86B | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.25B | +19.5% | +6.2% |
| June 30, 2025 | $6.83B | +7.4% | +9.0% |
| March 31, 2025 | $6.26B | -14.0% | +16.5% |
| December 31, 2024 | $5.37B | -28.4% | -11.4% |
| September 30, 2024 | $6.07B | -12.5% | -4.6% |
| June 30, 2024 | $6.36B | -9.8% | -12.6% |
| March 31, 2024 | $7.28B | -7.4% | -3.0% |
| December 31, 2023 | $7.51B | -5.0% | +8.3% |
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +47.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2007–2025 period, TEVA PHARMACEUTICAL INDUSTRIES LTD’s stockholders equity has declined by 42.9% (from $13.86 billion to $7.91 billion).
- The most recent figure is from TEVA PHARMACEUTICAL INDUSTRIES LTD’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: